Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
06 08 2020
Historique:
received: 08 10 2019
revised: 25 03 2020
accepted: 11 06 2020
pubmed: 9 7 2020
medline: 26 8 2020
entrez: 9 7 2020
Statut: ppublish

Résumé

Activation of dual-specificity tyrosine-phosphorylation-regulated kinases 1A and 1B (DYRK1A and DYRK1B) requires prolyl hydroxylation by PHD1 prolyl hydroxylase. Prolyl hydroxylation of DYRK1 initiates a cascade of events leading to the release of molecular constraints on von Hippel-Lindau (VHL) ubiquitin ligase tumor suppressor function. However, the proline residue of DYRK1 targeted by hydroxylation and the role of prolyl hydroxylation in tyrosine autophosphorylation of DYRK1 are unknown. We found that a highly conserved proline in the CMGC insert of the DYRK1 kinase domain is hydroxylated by PHD1, and this event precedes tyrosine autophosphorylation. Mutation of the hydroxylation acceptor proline precludes tyrosine autophosphorylation and folding of DYRK1, resulting in a kinase unable to preserve VHL function and lacking glioma suppression activity. The consensus proline sequence is shared by most CMGC kinases, and prolyl hydroxylation is essential for catalytic activation. Thus, formation of prolyl-hydroxylated intermediates is a novel mechanism of kinase maturation and likely a general mechanism of regulation of CMGC kinases in eukaryotes.

Identifiants

pubmed: 32640193
pii: S1097-2765(20)30423-8
doi: 10.1016/j.molcel.2020.06.021
pmc: PMC7849370
mid: NIHMS1609489
pii:
doi:

Substances chimiques

Isoenzymes 0
Proline 9DLQ4CIU6V
EGLN2 protein, human EC 1.14.11.29
Hypoxia-Inducible Factor-Proline Dioxygenases EC 1.14.11.29
Von Hippel-Lindau Tumor Suppressor Protein EC 2.3.2.27
Protein-Tyrosine Kinases EC 2.7.10.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Mitogen-Activated Protein Kinase 14 EC 2.7.11.24
VHL protein, human EC 6.3.2.-

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

376-389.e8

Subventions

Organisme : NCI NIH HHS
ID : R01 CA190891
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA101644
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA193313
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS061776
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA179044
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA131126
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178546
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239721
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Références

J Clin Invest. 2013 Jan;123(1):405-17
pubmed: 23241957
Cell. 2001 Oct 5;107(1):1-3
pubmed: 11595178
Cell. 2012 Jul 20;150(2):413-25
pubmed: 22817900
Elife. 2019 Sep 10;8:
pubmed: 31500697
Structure. 2013 Jun 4;21(6):986-96
pubmed: 23665168
Protein Sci. 2004 Aug;13(8):2059-77
pubmed: 15273306
Crit Rev Biochem Mol Biol. 2010 Apr;45(2):106-24
pubmed: 20199358
Sci Rep. 2015 Aug 03;5:12728
pubmed: 26234946
Biochem J. 2014 Jan 1;457(1):43-56
pubmed: 24134204
Cell Rep. 2016 Mar 22;14(11):2745-60
pubmed: 26972000
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Cell Metab. 2019 Oct 1;30(4):626-627
pubmed: 31577931
Genes Dev. 2011 Apr 15;25(8):801-13
pubmed: 21498570
J Biol Chem. 2005 Dec 23;280(51):42097-105
pubmed: 16257974
Development. 2011 Jun;138(12):2543-54
pubmed: 21610031
Sci Rep. 2017 Apr 4;7(1):619
pubmed: 28377597
Biomedicines. 2018 Mar 19;6(1):
pubmed: 29562667
Cancer Cell. 2005 Jan;7(1):77-85
pubmed: 15652751
Science. 2018 Jul 20;361(6399):290-295
pubmed: 30026228
FASEB J. 2011 Feb;25(2):449-62
pubmed: 21048044
Mol Cell Biol. 2007 May;27(9):3282-9
pubmed: 17325041
Sci Transl Med. 2016 Aug 31;8(354):354re3
pubmed: 27582061
J Mol Biol. 2009 Aug 7;391(1):1-11
pubmed: 19501598
Trends Biochem Sci. 2016 Nov;41(11):938-953
pubmed: 27594179
Structure. 2015 Mar 3;23(3):441-449
pubmed: 25661653
Dis Model Mech. 2016 Aug 1;9(8):839-48
pubmed: 27483355
Mol Cell. 2008 May 23;30(4):393-402
pubmed: 18498744
Nature. 2010 Jan 21;463(7279):318-25
pubmed: 20032975
J Biol Chem. 2010 Oct 8;285(41):31895-906
pubmed: 20696760
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90
pubmed: 15150404
Nature. 2016 Jan 14;529(7585):172-7
pubmed: 26735018
Nat Rev Mol Cell Biol. 2004 May;5(5):343-54
pubmed: 15122348
ACS Chem Biol. 2011 Mar 18;6(3):234-44
pubmed: 21090814
J Biol Chem. 1996 Feb 16;271(7):3488-95
pubmed: 8631952
J Mol Biol. 2008 Jan 4;375(1):70-9
pubmed: 17999933
Cell. 2005 Jun 17;121(6):925-36
pubmed: 15960979
J Biol Chem. 2005 Jul 8;280(27):25788-801
pubmed: 15851482
J Biol Chem. 2000 Jan 28;275(4):2431-8
pubmed: 10644696
J Med Chem. 2019 Jul 25;62(14):6512-6524
pubmed: 31274316
Cell Mol Life Sci. 2016 Feb;73(4):883-900
pubmed: 26346493
Sci Rep. 2017 Jul 25;7(1):6420
pubmed: 28743892
Cancer Res. 2002 Jun 1;62(11):3014-9
pubmed: 12036906
Fold Des. 1998;3(4):259-69
pubmed: 9710569
Nat Rev Cancer. 2014 Feb;14(2):77-91
pubmed: 24442143
Cell Cycle. 2012 Sep 15;11(18):3389-94
pubmed: 22918246
ChemMedChem. 2018 Jan 8;13(1):7-14
pubmed: 29210532
Oncogene. 2017 Jun 15;36(24):3450-3463
pubmed: 28114281
Mol Cell. 2004 Sep 10;15(5):661-75
pubmed: 15350212
Proteins. 1995 Nov;23(3):403-14
pubmed: 8710833
Neurosci Lett. 2007 Feb 8;413(1):77-81
pubmed: 17145134
J Neurosci Res. 2012 May;90(5):999-1010
pubmed: 22252917
J Mol Biol. 1994 Jan 21;235(3):983-1002
pubmed: 8289329
Cell. 1996 Apr 19;85(2):149-58
pubmed: 8612268
J Neurosci. 2010 Mar 17;30(11):4004-14
pubmed: 20237271
Cell. 2012 Aug 31;150(5):987-1001
pubmed: 22939624
FEBS J. 2009 Nov;276(21):6324-37
pubmed: 19796173
Front Oncol. 2012 Apr 12;2:35
pubmed: 22649785
Structure. 2015 Mar 3;23(3):435-436
pubmed: 25738382

Auteurs

Sang Bae Lee (SB)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA.

Aram Ko (A)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA.

Young Taek Oh (YT)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA.

Peiguo Shi (P)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA.

Fulvio D'Angelo (F)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA.

Brulinda Frangaj (B)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA.

Antonius Koller (A)

Proteomics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.

Emily I Chen (EI)

Proteomics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.

Timothy Cardozo (T)

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, NYU Langone Health, New York, NY 10016, USA.

Antonio Iavarone (A)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA; Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: ai2102@columbia.edu.

Anna Lasorella (A)

Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: al2179@columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH